Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· June 26, 2026
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
View original at nasdaq.comWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired (RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The workforce reduction is projected to deliver $10 million in annualised cost savings.
60% confidenceADC Therapeutics maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations.
60% confidenceDT120 ODT was generally well tolerated, with no serious adverse events or suicidality signal.
60% confidenceMerck KGaA expects to realise annual cost savings of approximately 140 million euros by the third year following the Bio-Techne deal closure.
60% confidenceThe company plans to resubmit the Cytisinicline NDA in Q4 2026, targeting a potential approval in H1 2027 if no further major issues arise.
60% confidence